RT Journal Article
SR Electronic
T1 Malignant pleural effusions as an alternative to biopsies for the detection of EGFR TKI sensitizing mutations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.08.19014167
DO 10.1101/2019.12.08.19014167
A1 George D’Souza
A1 Chirag Dhar
A1 Vishal Kyalanoor
A1 Lokendra Yadav
A1 Mugdha Sharmra
A1 S Mohammad Nawaz
A1 Sweta Srivastava
YR 2020
UL http://medrxiv.org/content/early/2020/01/06/2019.12.08.19014167.abstract
AB Lung cancer is the cause of a fourth of all cancer related deaths. About a third of all lung adenocarcinoma tumours harbour mutations on exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) gene. Detection of these mutations must be both accurate and timely as patients with certain EGFR mutations have better clinical outcomes when treated with EGFR Tyrosine kinase inhibitors. In our study, we utilized malignant pleural effusions (MPEs) as “ liquid biopsies” to detect EGFR mutations when tissue biopsies were unavailable. First, a direct sequencing approach was attempted leading to the detection of a common exon 19 deletion. We then tested the sensitivity of this method by sequencing the mutant DNA sample diluted with wildtype DNA. Signatures of this large deletion were detectable even in a 1 part mutant and 99 part wildtype mixture but with poor base-call confidence. MPEs consist of both wildtype inflammatory cells as well as mutant metastatic cells suggesting that this sequencing-based approach was going to limit our ability to detect single base pair mutations. To mitigate this limitation of sequencing, an EGFR mutant-specific quantitative polymerase chain reaction (PCR) based assay was used on a further n=10 pleural effusion samples (1 non-malignant pleural effusion as an internal negative control). 5/9 (55.55%) samples harboured EGFR mutations with 2/9 (22.22%) being exon 19 deletions and 3/9 (33.33%) had the S768I exon 20 mutation. These data suggest MPEs may be utilized to detect mutations even before a biopsy is made available. The high frequency of S768I mutations seen in our study suggests that cancer cells harbouring these mutations may be superior in their ability to migrate, home or reside in pleural fluid.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by a grant from the Advanced Research Wing of the Rajiv Gandhi University of Health Sciences, Bangalore.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no metadata associated with this study. All relevant data files are included as images or supplementary images.